Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Next Previous
Trial Profile

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Niraparib (Primary) ; Palbociclib (Primary) ; Rogaratinib (Primary) ; Bleomycin; Bleomycin; Bleomycin; Carboplatin; Docetaxel; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms UPSTREAM

Most Recent Events

  • 02 Nov 2023 Status changed from recruiting to active, no longer recruiting.
  • 24 Oct 2023 Results of substudy of of the I2 cohort , presented at the 48th European Society for Medical Oncology Congress
  • 16 Oct 2023 According to an innate pharma media release, the data from this trial will be presented at the ESMO, 2023, taking place October 20-24 in Madrid, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top